NCT05423769 - Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

Fingolimod

0.5 mg hard gelatine capsules

Trial Locations (2)

Neuropsychiatry department, Faculty of Medicine, Alexandria University Hospitals, Hadra University Hospital, Alexandria

Faculty of medicine Ain shams Research Institute-Clinical Research Center (MASRI-CRC), Cairo